An Open Label Phase 2 Study to Evaluate the Effects of a Local Anesthetic, Anti-inflammatory Medications and Compression Garments on RZL-012-Induced Adverse Events
Phase: PHASE1
Conditions: Submental Fat
Sponsor: Raziel Therapeutics Ltd.

 
RAZIEL THERAPEUTICS LTD. 
 
INVESTIGATIONAL NEW DRUG PROTOCOL 
 
RZL-012 
PROTOCOL NUMBER RZL-012-SMF-SWMTG-P2US-001 
VERSION 1.2 
15 NOVEMBER 2022 
 
AN OPEN LABEL PHASE 2 STUDY TO EVALUATE THE EFFECTS OF A LOCAL 
ANESTHETIC, ANTI-INFLAMMATORY MEDICATIONS AND COMPRESSION 
GARMENTS ON RZL-012-INDUCED ADVERSE EVENTS  
SPONSOR: 
Raziel Therapeutics, Ltd. 
10 Plaut Str. 
Rehovot, Israel 7610000 
 
CONFIDENTIAL  
This document is a confidential communication of Raziel Therapeutics, Ltd. Acceptance of this 
document constitutes agreement by the recipient that no unpublished information contained herein 
will be published or disclosed without prior written approval, except for disclosure to the 
appropriate Institutional Review Board and/or Regulatory Authority under the condition that 
confidentiality is maintained. 
 
Version 1.0:  03 AUGUST 2022 
Version 1.1: 19 September 2022 
Version 1.2: 15 November 2022 
 
 
 
 
    

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 2 of 44 
CONFIDENTIAL 
 
KEY CONTACTS FOR THE STUDY 
SPONSOR’S  
REPRESENTATIVES: 
 
Sponsor Contact 
Richard E. Lowenthal, MSc, MBA 
Program Manager 
Pacific-Link Research Inc. 
Cell: +1-858-335-1300 
Tel: +1-858-227-3008 
E-mail: richard@pacificlinkconsulting.com 
 
Study Director 
Racheli Gueta, PhD 
Raziel Therapeutics 
Director, Clinical Development 
Cell:  +972-50-7837597 
E-mail: racheli@raziel-therapy.com 
 
Study Medical Monitor 
Patricia Walker, MD  
E-mail: dr.patricia.walker@gmail.com 
 
Serious Adverse Event Reporting 
 
 
 
 
 
 
 
MedicalMonitorSupport@rhoworld.com 
Jamie_Chang@rhoworld.com 
SAE Hotline: 888-746-7231 
SAE Fax Line: 888-746-3293 
SAE Email: 
rho_productsafety@rhoworld.com 
 
 
 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 3 of 44 
CONFIDENTIAL 
 
TABLE OF CONTENTS 
LIST OF TABLES .......................................................................................................................... 6 
LIST OF FIGURES ........................................................................................................................ 6 
LIST OF APPENDICES ................................................................................................................. 6 
STATEMENT OF COMPLIANCE ................................................................................................ 9 
INVESTIGATOR STATEMENT ................................................................................................ 10 
1.0 
PROTOCOL SUMMARY ................................................................................................. 11 
1.1 
Protocol Synopsis............................................................................................................... 11 
1.2 
Schedule of Activities ........................................................................................................ 17 
2.0 
INTRODUCTION ............................................................................................................. 18 
1.1. 
Study Rationale .................................................................................................................. 18 
1.2. 
Scientific Background ........................................................................................................ 18 
1.2.1. 
Non-Clinical Studies ........................................................................................................ 18 
1.2.2. 
Clinical Studies ................................................................................................................ 19 
1.3. 
Risk-Benefit Assessment ................................................................................................... 20 
1.3.1. 
Identified RZL-012 Risks ................................................................................................ 20 
1.3.2. 
Benefits ............................................................................................................................ 21 
3.0 
STUDY OBJECTIVES AND ENDPOINTS ..................................................................... 22 
3.1 
Study Objectives ................................................................................................................ 22 
3.1.1 Primary Objective .............................................................................................................. 22 
3.1.2 Secondary Objectives......................................................................................................... 22 
3.2 
Study Endpoints ................................................................................................................. 22 
3.2.1 Primary Endpoint ............................................................................................................... 22 
3.2.2 Exploratory Endpoints ....................................................................................................... 22 
4.0 
STUDY DESIGN............................................................................................................... 23 
4.1 
Overall Design ................................................................................................................... 23 
4.2 
Rationale for Study Design ................................................................................................ 23 
4.3 
Rationale for Study Dose ................................................................................................... 24 
5.0 
STUDY POPULATION .................................................................................................... 24 
5.2 
Exclusion Criteria .............................................................................................................. 25 
6.0 
STUDY INTERVENTION ................................................................................................ 26 
6.1 
Study Intervention Administration .................................................................................... 26 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 4 of 44 
CONFIDENTIAL 
 
6.1.1 Study Intervention Description .......................................................................................... 26 
6.2 
Preparation/Handling/Storage/Accountability ................................................................... 28 
6.3 
Study Intervention Compliance ......................................................................................... 29 
6.4 
Prior and Concomitant Medications .................................................................................. 29 
7.0 
STUDY INTERVENTION DISCONTINUATION .......................................................... 29 
8.0 
STUDY ASSESSMENTS AND PROCEDURES ............................................................. 30 
8.1 
Medical History ................................................................................................................. 30 
8.2 
Height ................................................................................................................................. 30 
8.3 
Weight ................................................................................................................................ 30 
8.4 
Pregnancy Tests ................................................................................................................. 30 
8.5 
Complete Physical Examination ........................................................................................ 30 
8.6 
Clinician-Chin Assessment Tool (C-CAT) ........................................................................ 31 
8.7 
Subject – Self-Chin Assessment Tool (S-CAT) ................................................................ 31 
8.8 
Magnetic Resonance Imaging (MRI) ................................................................................. 32 
8.9 
2-D Standardized Photography .......................................................................................... 33 
8.10 Subject’s Satisfaction Questionnaire ................................................................................. 33 
8.11 Biochemistry ...................................................................................................................... 35 
8.12 Vital Signs .......................................................................................................................... 35 
8.13 ECG.................................................................................................................................... 35 
8.14 Adverse Events and Serious Adverse Events .................................................................... 35 
8.14.1 Collection of Adverse Events Data .................................................................................... 35 
8.14.2 Serious Adverse Events ..................................................................................................... 37 
8.14.3 Reporting Requirements for Serious Adverse Events ....................................................... 37 
8.14.4 Reporting pregnancy .......................................................................................................... 38 
8.14.5 Recording of Serious Adverse Events ............................................................................... 38 
9.0 
STATISTICAL CONSIDERATIONS............................................................................... 39 
9.1 
Sample Size Determination................................................................................................ 39 
9.2 
Analysis Data Sets ............................................................................................................. 39 
9.3 
Endpoints Analyses ............................................................................................................ 39 
9.4 
Safety ................................................................................................................................. 39 
10.0 DATA COLLECTION, STUDY MONITORING, AND DATA DISCLOSURE ............ 40 
10.1 Data Collection and Reporting........................................................................................... 40 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 5 of 44 
CONFIDENTIAL 
 
10.2 Study Monitoring ............................................................................................................... 40 
10.3 Audit and Inspection .......................................................................................................... 40 
10.4 Deviation from Clinical Trial Protocol .............................................................................. 40 
10.5 Retention of Records.......................................................................................................... 41 
10.6 Data Disclosure and Subject Confidentiality ..................................................................... 41 
11.0 PROTECTION OF HUMAN SUBJECTS ........................................................................ 42 
11.1 Basic Principles .................................................................................................................. 42 
11.2 Institutional Review Board/Ethics Committee .................................................................. 42 
11.3 Informed Consent............................................................................................................... 42 
11.4 Subject Health Injury and Insurance .................................................................................. 43 
11.5 Completion of the Study .................................................................................................... 43 
 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 6 of 44 
CONFIDENTIAL 
 
LIST OF TABLES 
Table 1 
Estimated Cumulative Exposure from Clinical Studies ............................................. 19 
Table 2 
Clinician Chin Assessment Tool (C-CAT) ................................................................. 31 
Table 3 
Self Chin Assessment Tool (S-CAT) ......................................................................... 32 
Table 4 
Severity Assessment of Adverse Events .................................................................... 36 
Table 5 
Contact Information for SAE Reporting .................................................................... 38 
 
LIST OF FIGURES 
Figure 1 
Submental Injection Pattern........................................................................................ 28 
 
LIST OF APPENDICES 
Appendix A:   Photographic Standards of the Face Area ....................................................... 44 
 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 7 of 44 
CONFIDENTIAL 
 
LIST OF ABBREVIATIONS 
ABBREVIATION 
DEFINITION 
ADR 
Adverse drug reaction 
AE 
Adverse event 
ALP 
Alkaline phosphatase 
ALT 
Alanine transaminase  
AST 
Aspartate aminotransferase 
BMI 
Body mass index 
BUN 
Blood urea nitrogen 
CBC 
Complete blood count 
C-CAT 
Clinician Chin Assessment Tool 
cGMP 
Current Good Manufacturing Practices 
CI 
Confidence interval 
cm 
Centimeter 
CNS 
Central nervous system 
CRF 
Case report form 
CV 
Coefficient of variable 
DD 
Dercum’s disease 
ECG 
Electrocardiograms 
FDA 
Food and Drug Administration 
GLP 
Good Laboratory Practice 
IB 
Investigator’s Brochure 
ICF 
Informed Consent Form 
ICH-GCP 
International Conference on Harmonization Good Clinical Practice 
IND 
Investigational New Drug 
INR 
International normalized ratio 
IRB/EC 
Institutional Review Board/Ethics Committee  
kg 
Kilogram 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 8 of 44 
CONFIDENTIAL 
 
ABBREVIATION 
DEFINITION 
LDH 
Lactate dehydrogenase  
MedDRA 
Medical Dictionary for Regulatory Activities 
mg 
milligram 
mL 
milliliter  
MOA 
Mechanism of action 
MRI 
Magnetic resonance imaging 
N 
Number of subjects 
NSAID 
Non-steroidal anti-inflammatory drugs 
PT 
Prothrombin time 
PTT 
Partial thromboplastin time 
RBC 
Red blood count 
SAE 
Serious adverse event 
S-CAT 
Subject Chin Assessment Tool 
SMF 
Submental fat 
SOP 
Standard operating procedure 
TEAE 
Treatment emergent adverse event(s) 
US/USA 
United States of America 
WBC 
White blood cell 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 9 of 44 
CONFIDENTIAL 
 
STATEMENT OF COMPLIANCE 
This clinical trial will be conducted in compliance with the protocol, International Conference on 
Harmonization Good Clinical Practice E6 and the applicable regulatory requirements. 
 
 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 10 of 44 
CONFIDENTIAL 
 
INVESTIGATOR STATEMENT 
I have read and understand the protocol and agree to implement the study in accordance with the 
procedures set forth in the protocol and in accordance with the Sponsor's guidelines, all 
applicable government regulations, and the International Conference on Harmonization Good 
Clinical Practice Guidelines E6 (ICH-GCP). 
I will maintain accurate source documents from which data are transcribed onto case report 
forms and accurate drug accountability records that show the receipt and disposition of all study 
drugs. 
I will provide adequate protocol training to my associates, colleagues, and employees assisting in 
the conduct of the study. 
I will obtain Institutional Review Board/Ethics Committee (IRB/EC) approval of the protocol and 
Informed Consent Form (ICF) prior to enrollment of subjects in the study. I understand that any 
modifications to the protocol made during the course of the study must first be approved by the 
IRB/EC prior to implementation except when such modification is made to remove an immediate 
hazard to the subject. 
I will ensure that a fully executed IRB-approved Informed Consent Form is obtained from each 
subject prior to initiation of any study procedures. 
I will report (within 24 hours) any serious adverse event, regardless of relationship to study drug, 
or pregnancy that occurs during the course of the study, in accordance with the procedures 
described in Section 8.14.3 of the protocol. I will notify the Sponsor if I become aware that a 
partner of a study subject becomes pregnant while the subject was receiving this study drug. 
I will submit all protocol inclusion/exclusion violations to the Medical Monitor for approval prior 
to enrollment of the subject in the study. 
I will allow the Sponsor, Raziel Therapeutics Ltd. (Raziel) and its agents, as well as the United 
States (U.S.) Food and Drug Administration (FDA) and other regulatory agencies to inspect study 
facilities and pertinent records at reasonable times and in a reasonable manner, ensuring subject 
confidentiality. If I am notified that this study is to be inspected by a regulatory agency, I will 
notify the Sponsor as soon as possible thereafter (no later than one week). 
This protocol contains information that is proprietary to Raziel.  The information contained herein 
is provided for the purpose of conducting a clinical trial for Raziel. 
The contents of this protocol may be disclosed to study personnel under your supervision and to 
your IRB/EC. The contents of this protocol may not be disclosed to any other parties (unless such 
disclosure is required by government regulations or laws) without the prior written approval of 
Raziel. 
 
______________________     ______________________________       
________________ 
Investigator’s Name                Investigator’s Signature 
 
 
Date 
 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 11 of 44 
CONFIDENTIAL 
 
1.0 PROTOCOL SUMMARY 
1.1 
Protocol Synopsis 
Study Title 
An Open Label Phase 2 Study to Evaluate the Effects of a Local Anesthetic, Anti-
inflammatory Medications and Compression Garments on RZL-012-Induced Adverse 
Events (RZL-012-SMF-SWMTG-P2US-001) 
Phase 
Phase 2 
Study Drug 
RZL-012 
Study Objectives 
and Endpoints 
Primary Objective:  
• 
To compare the benefits of lidocaine, methylprednisolone,  Celecoxib +cetirizine or 
compression dressings on RZL-012-induced adverse events 
Secondary Objectives: 
• 
To test the safety and tolerability profile of combining lidocaine, methylprednisolone, 
Celecoxib + cetirizine or compression garment with RZL-012 
Primary Endpoint: Safety and tolerability profile of combining lidocaine, methylprednisolone 
,  Celecoxib +cetirizine or a compression garment with RZL-012 
Exploratory  Endpoints:  
• 
Proportion of subjects who have at least a 1-grade improvement in the C-CAT on Day 
84 versus baseline in subjects receiving RZL-012 alone or in combination with other 
medications.  
• 
Proportion of subjects who have at least a 1-grade improvement in the S-CAT on Day 
84 versus baseline in subjects receiving RZL-012 alone or in combination with other 
medications. 
• 
Proportion of subjects who have at least a 1-grade improvement in both C-CAT and S-
CAT on Day 84 versus baseline in subjects receiving RZL-012 alone or in combination 
with other medications. 
• 
Proportion of subjects who have at least a 2-grade improvement in both C-CAT and S-
CAT on Day 84 versus baseline in subjects receiving RZL-012 alone or in combination 
with other medications. 
• 
Changes in SMF volume measured by MRI scans on Day 84 versus baseline in subjects 
receiving RZL-012 alone or in combination with other medications. 
• 
Satisfaction in subjects receiving RZL-012 alone or in combination with other 
medications. 
Study Design 
This is a Phase 2, open-label, 2-stage, adaptive-design study in which subjects will be 
randomized into one of 5 treatment groups comprised of RZL-012 with or without 
additional study treatments: 
1. RZL-012 alone 
2. RZL-012 and 1% lidocaine with 1:100,000 epinephrine (on Day 1) – 5ml lidocaine will 
be injected 10 minutes before RZL-012 treatment 
3. RZL-012 and oral methylprednisolone dose pack (8 mg (2 tablets) on Day 1 before 
treatment followed by 16 mg after treatment (as per Instructions for Use)). From Day 2, a 
daily tapering off by 4 mg until Day 6 will be administered per Rx Instructions for use. 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 12 of 44 
CONFIDENTIAL 
 
4. RZL-012 and Celecoxib and cetirizine (200 mg Celecoxib BID and 10 mg cetirizine BID 
on Days 1, 2, 3, 4, 5 and 6) 
5. RZL-012 + sling/pressure garment (until Day 6) 
In the first stage of the study, 5 subjects will be randomized into each of the treatment 
groups. Study outcomes will be assessed up to one week thereafter to determine the need to 
modify additional study treatments. Subsequently up to 10 additional subjects will be 
randomized into each of the treatment groups for the second stage of the study.   
For each subject, the study will consist of a screening period, baseline period in which 
subjects will receive a single treatment session of RZL-012 and a follow-up period.  RZL-
012 will be administered during a single treatment session via multiple injections into the 
submental area under the chin. Subjects will thereafter be monitored for safety and efficacy 
for at least 84 days. 
Each subject will be treated with the same dose of RZL-012 : 
• 
RZL-012 (concentration of injected solution 50 mg/mL RZL-012) of 7.5 mg/0.15 
mL/injection point that results in a total dose/volume of 240±30mg mg/4.8±0.6 
mL RZL-012, 
Each subject will receive additional study treatments in accordance with the treatment 
group to which the subject is randomized. 
Screening Period:   
Subjects will undergo screening within 28 days prior to being treated with RZL-012. 
During the screening period subjects will be assessed for study eligibility by evaluation of 
subjects’ SMF using S-CAT , C-CAT, biochemistry blood tests, MRI,  2D photography. 
ECG will also be conducted during the screening visit. Following completion of study 
procedures (including MRI), subjects will be randomized in order for the PI to administer 
subjects with the Rx prescription, if appropriate (i.e., Celecoxib / cetirizine). 
Day 1/Baseline: 
At Baseline visit, subjects will be given with their randomized medication if appropriate. 
Subjects will receive a single multi-injection treatment of RZL-012 on Day 1.  AEs will be 
recorded. Subjects will be asked about their pain levels using VAS. Additional 
medications/treatments, will be given according to its instructions for use. 
Day 1-Day 84 Follow-Up Period 
Subjects will return to the site for study visits on Days 2, 4, 7, 14, 21, 28, 56 and 84 for 
efficacy and safety assessments. 
For subjects having unresolved AEs on Day 84, an unscheduled visit will be set 6-8 weeks 
after Day 84 to verify the resolution of the AE. On that visit, follow up of using 
photographs  C-CAT and S-CAT will also be conducted.  
Subjects will be advised to continue their regular diet and physical activity during the study. 
Safety assessments include vital signs, ECG, AEs severity assessment, and treatment area 
evaluation. Treatment area evaluations including, but not limited to evaluation of edema, 
bruising, dysphasia, dysphonia, erythema, dyspigmentation, induration, numbness, pain, 
paresthesia, pruritus, skin ulceration and necrosis, injury to the marginal mandibular nerve, 
vascular and nerve injury and tissue damage to nearby vulnerable anatomic structures. 
Specifically, degree of swelling severity will be assessed as a function of time and in each 
visit Subjects will be asked about their pain levels using VAS. Pain at injection site will not 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 13 of 44 
CONFIDENTIAL 
 
be recorded as an AE but the information regarding pain will be obtained from the VAS 
scores completed by the subject. Concomitant medications will be recorded.  
Sample Size 
Up to 75 subjects (5 in each treatment group in stage 1 of the study and up to 10 subjects in 
each treatment group in stage 2 of the study). 
Study 
Population 
Adult volunteers age 18 to 65 years who have consented to participate in this study. 
Main Inclusion 
Criteria 
For a subject to be eligible for this study, he or she must meet all of the following criteria: 
1. Is a male or female subject between the ages of 18 and 65 years, inclusive. 
2. Has body mass index (BMI) between >22  kg/m2 and <40  kg/m2. 
3. Has SMF  bulge that is contiguous and fits to 32±4 injections sites according to a grid 
with 1 centimeter (cm) distance between injection points. 
4. Has grade 3 to 4 of SMF as rated by both the C-CAT and S-CAT. 
5. Has stable weight, with no fluctuation of >5 kg in the past 12 months. 
6. If female, is not pregnant or breastfeeding based on the following: 
a. 
agree to the use of highly effective contraceptive methods for at least 2 weeks 
before baseline until 4 weeks after the last day of study drug and a negative 
serum pregnancy test (ß-hCG) at screening and negative urine pregnancy test at 
baseline; or  
b. is abstaining  
c. 
is of nonchildbearing potential defined as clinically infertile as the result of 
surgical sterilization (hysterectomy, bilateral tubal ligation, and/or bilateral 
oophorectomy); or  
d. is confirmed postmenopausal status (defined as either having amenorrhea for ≥ 
12 consecutive months without another cause or documented serum follicle-
stimulating hormone (FSH) level > 40 mIU/mL or another documented medical 
condition (e.g., was born without a uterus)) 
NOTE: The following are considered highly effective contraceptive methods: 
hormonal oral contraceptives, injectables, and patches; intrauterine devices; 
double-barrier methods (synthetic condom, diaphragm, or cervical cap used with 
spermicidal foam, cream, or gel); and male partner sterilization. 
7. If male (with or without vasectomy), agree to the use of highly effective contraceptive 
methods as listed above in criteria 7 as well as to use a barrier method, e.g. condom , 
from study check-in until 7 days after drug injection. 
8. Is willing to avoid strenuous exercise for seven (7) days post treatment. 
9. Is able to adhere to the visit schedule and protocol requirements and be available to 
complete the study. 
10. Is willing and able to sign an Institutional Review Board (IRB) approved informed 
consent form (ICF) indicating that they are aware of the investigational nature of the 
study. 
Main Exclusion 
Criteria  
Subjects must NOT meet any of the following Exclusion criteria to be eligible for 
enrollment: 
1. Is unable to tolerate subcutaneous injections. 
2. Has any systemic disease including but not limited to gastritis or ulcers, renal 
dysfunction, hypertension, liver disease, glaucoma, diabetes and/or cardiovascular 
disease, , regardless of whether the condition is controlled with medication. 
 
3. Has any contraindications to oral corticosteroids (methylprednisolon), NSAIDs (e.g.,  
Celecoxib) or non-sedative antihistamines (e.g. cetirizine) 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 14 of 44 
CONFIDENTIAL 
 
4. Has skin laxity (i.e., elastosis, skin crepiness, skin redundancy, skin draping, vertical 
and/or horizontal skin bands and folds, blunting of cervical mental angle, loss of 
opposition of skin to underlying neck structures due to skin laxity) that could obscure 
the evaluation and treatment of SMF. 
5. Has any scars, unshaven hair, tattoos, facial hair or jewelry on or near the proposed 
treatment area. 
6. Has presence of structures or confounding factors that may interfere with assessing 
SMF such as but not limited to enlarged submandibular salivary and/or parotid glands, 
micrognanthia, chin implant, soft tissue volume augmentation of chin and/or jawline, 
pronounced platysmal bands and deep necklace lines or presence of facial jowls that 
could obscure the evaluation of SMF.  
7. Has a fat bulge under the chin that is too large to be adequately treated by 32±4 
contiguous injections on a 1cm grid . 
8. Has a fat bulge under the chin that is of an insufficient volume to allow 32±4 injections 
within a contiguous 1 cm grid.  
9. Has significant history or current evidence of a medical, psychological or other 
disorder that, in the Investigator’s opinion, would preclude enrollment in the study. 
10. Has an active bacterial, fungal, or viral infection in the proposed treatment area. 
11. Has a pre-existing skin condition in the submental region that, at the Investigator’s 
discretion, may confound evaluation or analysis. 
12. Has previously had treatments or surgery in the submentum, such as but not limited to, 
focused ultrasound, radiofrequency, cryolipolysis, liposuction, sodium deoxycholate, or 
neck lift. 
13. Has pre-existing neurological or gastrointestinal condition leading to dysphagia, 
dysphonia, or facial nerve palsy. 
14. Has Dercum’s Disease. 
15. Has allergic reactions to injectables  
16. Has allergic reactions to cetirizine or Celecoxib. 
17. Has any pre-existing medical condition other than increased SMF that, at the 
Investigator’s discretion, may result in increased submental fullness, such as but not 
limited to, thyroid enlargement, goiter, cervical lymphadenopathy, etc. 
18. Has a planned fat reduction procedure of any variety to the submental region for the 
duration of the study. 
19. Has medication or a history of coagulopathy. 
20. Has a history or family history of venous thrombotic disease. 
21. Has been treated chronically at least three (3) months prior to study entry with systemic 
steroids or immunosuppressive drugs. 
22. Has been treated chronically at least one (1) week prior to study entry with non-
steroidal anti-inflammatory drugs (NSAIDs)  
23. Has used anticoagulation therapies that may increase bleeding or bruising (i.e., aspirin, 
ibuprofen/Celecoxib, warfarin, vitamins, and herbal preparations) for seven (7) days 
prior to treatment. 
24. Has had treatment with botulinum toxin injections in the neck or chin area within nine 
(9) months prior to screening. 
25. Current participation or participation within three (3) months prior to the start of this 
study in a drug or other investigational research study. 
26. Claustrophobia or MRI incompatible device or implant. 
Dosage and 
Administration 
of Study Drug 
Subjects will receive study treatments in accordance with the treatment group to which the 
subject is randomized: 
 
 
Group 1 
Group 2 
Group 3 
Group 4 
Group 5 
Day 1 
RZL-012 
RZL-012 + 1% 
lidocaine with 
RZL-012 + 
methylpredn
RZL-012 + 
RZL-012 + 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 15 of 44 
CONFIDENTIAL 
 
1:100,000 
epinephrine 
(10  minutes  
prior to RZL-
012) 
 
isolone dose 
pack (the 
first dose of 
2 tablets 
(8mg) is 
administered
1-2 hours 
prior to 
RZL-012) 
 
A total of 24 
mg (16 mg 
after RZL-
012, as per 
IFUs) 
 
200 mg 
Celecoxib 
BID and 10 
mg 
cetirizine 
BID (the 1st 
dose is 
administere
d 1-2 hours 
prior to 
RZL-012). 
pressure 
garment 
Day 2 
 
 
20 mg 
methylpredn
isolone 
200 mg 
Celecoxib 
BID and 10 
mg  
cetirizine 
BID 
pressure 
garment 
Day 3 
 
 
16 mg 
methylpredn
isolone 
200 mg 
Celecoxib  
BID and 10 
mg 
cetirizine 
BID 
pressure 
garment 
Day 4 
 
 
12 mg 
methylpredn
isolone 
200 mg 
Celecoxib  
BID and 10 
mg Zyrtec 
BID 
pressure 
garment 
Day 5 
 
 
8 mg 
methylpredn
isolone 
200 mg 
Celecoxib  
BID and 10 
mg 
cetirizine 
BID 
pressure 
garment 
Day 6 
 
 
4 mg 
methylpredn
isolone 
200 mg 
Celecoxib  
BID and 10 
mg 
cetirizine 
BID 
pressure 
garment 
BID = twice daily,  
 
RZL-012 will be administered via multiple injections (32±4) for a total dose of 240±30 mg. 
Each injection point will be dosed with 7.5 mg RZL-012 in a volume of 0.15 mL/injection 
site. The total injection volume for all groups will be 4.8 mL±0.6. 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 16 of 44 
CONFIDENTIAL 
 
Subjects will be injected with RZL-012 perpendicularly (90°) to the skin. An ice pack will 
be placed on the injected area for pain relief immediately after injection. Subjects will 
remain seated in the injection position for an additional 10 minutes after dosing. 
The injection pattern will be based on a submental area shaped grid in which the distance 
between rows and columns will be 1 cm, as seen in the figure below. The Investigator will 
choose 32±4 sequential points on the grid that will mark the injected area according to SMF 
fullness and convexity. The treatment area boundary: superiorly by a line 1 cm inferior to 
the mandibular margin, laterally by the sternocleidomastoid muscles, and inferiorly by the 
hyoid bone. 
 
 
Safety Analysis 
AEs will be collected and reviewed to evaluate the safety and tolerability of RZL-012. AE 
collection will begin after dosing and will end at on Day 84. For subjects having unresolved 
AEs on Day 84, an unscheduled visit will be set 6-8 weeks after Day 84 to verify the 
resolution of the AE.  
Other safety measures will include vital sign measurements, laboratory parameters, ECG, 
and treatment area evaluation including, but not limited to evaluation of edema, bruising, 
dysphasia, dysphonia, erythema, dyspigmentation, induration, numbness, pain, paresthesia, 
, pruritus, skin ulceration and necrosis, injury to the marginal mandibular nerve, vascular 
and nerve injury and tissue damage to nearby vulnerable anatomic structures.  Specifically, 
swelling severity will be assessed in each visit, subjects will be asked about their pain 
levels. Pain at injection site will not be recorded as an AE but the information regarding 
pain will be obtained from the VAS scores completed by the subject. AEs related to nerve 
injury will be AEs of special interest. Concomitant medications will be recorded.  
Statistical 
Analysis 
All measured variables and derived parameters will be listed individually and, if 
appropriate, tabulated by descriptive statistics. 
For categorical variables, summary tables will be provided giving sample size, absolute and 
relative frequency, and 95% confidence interval (CI) for proportions by study arm. 
For continuous variables, summary tables will be provided giving sample size, arithmetic 
mean, standard deviation, coefficient of variations (CV%), median, minimum and 
maximum, and 95% CI for means of variables by study arm. 
Primary endpoint and exploratory endpoints  will be analyzed in descriptive manner. 
 The data will be analyzed using the SAS version 9.4 (SAS Institute, Cary North Carolina). 
Study Duration 
It is planned that each subject will participate in the study for 4 months, which comprises a 
screening period, baseline/treatment period, and follow up period.  
Study Centers 
6 clinical centers 
 
 
 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 17 of 44 
CONFIDENTIAL 
 
 
1.2 
Schedule of Activities 
 
Study Procedure 
Screening 
Baseline 
(Treatment) 
Post Baseline Visit Schedule 
Study Day 
Day (-28) 
through 
Day (-1) 
Day  1 
Day 2 
Day 4 
Day 
7 
Day 
14 
Day 
21 
Day 
28 
Day 
56 
Day 
84 
Signed informed 
consent 
X 
 
 
 
 
 
 
 
 
 
Medical history 
X 
 
 
 
 
 
 
 
 
 
Physical Exam 
X 
 
 
 
X 
 
 
 
 
X 
Concomitant 
Medication 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Pregnancy ß-hCG 
X 
 
 
 
 
 
 
 
 
 
Pregnancy urine 
test (women) 
 
X 
 
 
 
 
 
 
 
X 
Weight 
measurements  
X 
X 
 
 
 
 
 
X 
 
X 
Height 
measurement 
X 
 
 
 
 
 
 
 
 
 
Biochemistry Lab 
parameters 
X 
 
X 
 
X 
 
 
X 
 
X 
 
ECG 
X 
 
 
 
X 
 
 
 
 
X 
 
Vital signs  
X 
Pre X post 
X 
X 
X 
X 
X 
X 
X 
X 
Randomization 
X 
 
 
 
 
 
 
 
 
 
Injection of RZL-
012 
 
X 
 
 
 
 
 
 
 
 
Clinician Chin 
Assessment Tool 
(C-CAT) 
X 
X 
 
 
 
 
 
X 
X 
X 
Subject- Self-
Chin Assessment 
Tool (S-CAT) 
X 
X 
 
 
 
 
 
X 
X 
X 
Subject’s 
Satisfaction 
questionnaire for 
SMF appearance 
X 
 
 
 
 
 
 
X 
X 
X 
2D Standardized 
photography 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
MRI 
X 
 
 
 
 
 
 
 
 
X 
AEs including 
VAS 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 18 of 44 
CONFIDENTIAL 
 
2.0 INTRODUCTION 
1.1. 
Study Rationale 
The recent clinical study (RZL-012-SMF-P2b-US-001) was a double-blind, randomized, three-
arm, placebo-controlled Phase 2b study that tested the efficacy and safety of RZL-012 injections 
into the submental fat in 151 subjects. Single administration of high dose RZL-012 (50mg/ml) 
resulted in a clinically meaningful reduction in submental fat. The efficacy of the RZL-012 high 
dose was higher than that of the low dose and of the placebo. Local injection-site reactions were 
the most commonly reported AEs with injection-site pain, nodules induration and edema being 
clearly RZL-012 related. Injection-site severe swelling in the submental area was shown to be 
associated with additional AEs such as dysphagia, dysphonia, and dyspnea. 
This clinical trial will assess ways to reduce AEs related to swelling and pain.  
1.2. 
Scientific Background  
RZL-012 is a cytolytic drug - it disrupts cell membrane integrity which results in necrotic cell 
death. RZL-012 demonstrated a cell killing effect on cultured adipocyte, fibroblasts and HepG2 
cells with IC50 values ranging between 20-100 µM. In vivo pig studies demonstrated liponecrosis 
at the injection site, followed by a transient inflammatory response and finally, a healing process 
in which fibrotic tissue replaces previous fat tissue. Necrosis of fat tissue at the injection site was 
seen as early as 24 hours after injection and was still evident 2 weeks later but completely cleared 
by 12 weeks post dosing. A macrophage-mediated inflammatory response was also prominent at 
24 hours and 14 days after injection with only minimal signs of inflammation remaining by 12 
weeks post dosing. Fibrosis showed a different pattern compared with liponecrosis and 
inflammation, starting at 14 days post dosing and becoming much more prominent at 12 weeks 
post dosing. In essence, RZL-012 enabled de-novo generation of fibrotic tissue to replace excess 
fat tissue at selected anatomical sites. 
To date, Raziel has conducted several clinical studies under INDs to evaluate the safety and 
efficacy of RZL-012 for local fat reductions, including obesity (INDs 119941, 133324), lipomas 
of Dercum’s Disease patients and SMF (IND 135762) and SMF and flank reduction (IND 154260). 
Across all clinical trials approximately 222 subjects have received single doses of RZL-012 
ranging from 5 mg to 412 mg per subject. 
1.2.1. Non-Clinical Studies 
The mechanism of action of RZL-012 has been studied in in-vitro studies and in in-vivo studies in 
pigs (domestic Yorkshire crossbred swine). Pigs were chosen for these studies because their 
subcutaneous fat resembles that of humans. RZL-012 injected into SC pig fat first caused 
liponecrosis at the injection site, followed by a transient inflammatory response and finally by a 
healing process in which fibrotic tissue replaced previous fat tissue.  
Safety pharmacology studies of RZL-012 in male Sprague Dawley rats demonstrated that RZL-
012 has no effects on the central nervous system functions, or on the respiratory system, on  ECG 
parameters or blood pressure.  Safety pharmacology studies of RZL-012 in domestic Yorkshire 
crossbred swine demonstrated no effects on ECG parameters or blood pressure. 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 19 of 44 
CONFIDENTIAL 
 
Single and chronic toxicology studies were conducted in Sprague-Dawley rats and in pigs. Local, 
dose-related skin reactions included fibrosis, inflammation, degeneration/necrosis, atrophy and 
epidermal hyperplasia. Systemic reactions included increased blood urea nitrogen [BUN], 
increased creatinine and aspartate aminotransferase [AST] levels and histopathological changes in 
kidneys (necrosis in tubular epithelium). 
Rat embryo-fetal development (EFD) and fertility and early embryo-fetal development (FEED; 
fertility) studies demonstrated no changes on fertility and reproduction in males and females. 
Further details on mechanism of action, safety pharmacology, and toxicology of RZL-012 are 
provided in the investigator’s brochure (IB). 
1.2.2. Clinical Studies 
To date, approximately 222 subjects have received single doses of RZL-012 ranging from 5 mg 
to 412 mg per subject across 8 clinical trials (Table 1). 
Table 1 
Estimated Cumulative Exposure from Clinical Studies 
Study Number 
Study Population 
RZL-012 
Placebo 
N 
Dose (mg) 
N 
RZL-012-P0-US-001 
Healthy Subjects (Phase 0 obesity) 
18 
5-20 
6 
RZL-012-P2a-US-001 
Healthy subjects (Phase 2a obesity) 
24 
40-180 
7 
RZL-012-FD-P2a-US-001 
Lipedema (Phase 2a) 
6 
60-80 
0 
RZL-012-FD-P2a-US-001 
DD (Phase 2a) 
6 
30-40 
0 
RZL-012-DD-P2b-US-001 
DD (Phase2b) 
29 
40-240 
18 
RZL-012-SMF-P2a-US-001 Submental Fat (Phase 2a) 
18 
70-210 
10 
RZL-012-hADMEC14-001 
Human ADME study 
6 
72.9 
0 
RZL-012-SMF-P2b-US-001 Submental Fat (Phase 2b) 
103 
142-270 
48 
RZL-012-FL-P2US-001 
Subjects with Flank Fat 
12 
412 
0 
Overall Total Number of Subjects 
222 
- 
89 
All clinical trials were conducted in the US, and in all trials RZL-012 was administered via 
multiple injections during a single injection session.  
1.2.2.1. 
Clinical Trials in SMF 
Three clinical trials have been conducted to assess the efficacy and safety of RZL-012 in reducing 
fat in the submental area. One trial (study RZL-012-SMF-P2a-US-001) was a single-blind, 
randomized, placebo-controlled, phase 2a, 2-cohort study. The second trial (study RZL-012-SMF-
P2b-US-001) was a double-blind, randomized, three-arm, placebo-controlled Phase 2b study. Both 
studies were completed. The third trial (Study RZL-012-SMFC-P2-US-001) is An Open-Label 
Phase 
2 
Study 
to 
Compare 
the 
Pharmacokinetics, 
Efficacy 
and 
Safety 
of  

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 20 of 44 
CONFIDENTIAL 
 
RZL-012 in Chinese Subjects Seeking Submental Fat Reduction vs. Non-Chinese Subjects 
Seeking Submental Fat Reduction. Study enrollment has been initiated recently.  
Study RZL-012-SMF-P2a-US-001 
Study RZL-012-SMF-P2a-US-001.2 was a single-blind study conducted in 28 subjects with 
submental fat. An assessment of efficacy was based on the Physician global assessment scale, SMF 
volume change (MRI), and subject's Face-Q satisfaction questionnaire. 
All subjects received a single dosing session and were followed up for 84 days. RZL-012 low dose 
(N=8) received an average injected dose of 80 mg/subject, RZL-012 high dose (N=10) an average 
injected dose of 158.5 mg/subject. Ten subjects received placebo. Based on a physician global 
assessment scale (physicians were not blinded to study treatment), 17/18 of RZL-012 treated 
subjects demonstrated an improvement in submental fat appearance on 84 days after treatment vs. 
baseline. None of the placebo subjects demonstrated any change in submental fat appearance on 
Day 84 vs. baseline. According to the Subject Face-Q Questionnaire (subjects were blinded to 
study treatment), subjects reported satisfaction regarding perceived effects of RZL-012 on 
submental fat appearance. The RZL-012 low dose group had a 2.4-fold increase in mean subject 
satisfaction score, the RZL-012 high dose group showed a 2.5-fold increase in mean subject 
satisfaction score while the placebo group did not demonstrate an improvement in satisfaction on 
Day 84 vs. baseline. These Clinician Reported Outcome (CRO) and Patient Reported Outcome 
(PRO) were correlated with the objective measure of MRI, determined on Day 84 vs. baseline. 
The high dose RZL-012 group showed a volume reduction of -22.2% ± 14.9 (p<0.05 vs the placebo 
group), the low dose RZL-012 group showed a volume reduction of -10.6% ± 14.5 (p=0.67 vs the 
placebo group, NS) and the placebo group demonstrated a volume reduction of -0.4% ± 13.9. 
Study RZL-012-SMF-P2b-US-001 
Study RZL-012-SMF-P2b-US-001 was a double-blind, randomized, three-arm, placebo-controlled 
Phase 2b study conducted in 151 subjects with submental fat. Forty-eight subjects were 
randomized to the placebo group, 53 subjects to the RZL-012 low dose (183.6 mg) group and 50 
subjects to the RZL-012 high dose (270 mg) group. An assessment of efficacy was based on the 
Clinician Assessment Tool (C-CAT), Subject Self-Chin Assessment Tool (S-CAT); and SMF 
volume via MRI and caliper-measured submental thickness. Raziel met the primary and secondary 
endpoints of the study. The proportion of subjects that had an improvement of at least 1 grade 
using the C-CAT and proportion of subjects who had an improvement of at least 2 grades in both 
C-CAT and S-CAT in the same subject were statistically significantly higher in RZL-012 high 
dose vs. placebo.  The MRI results demonstrated a volume reduction of -14.9%, -8.3% and no 
reduction in volume in RZL-012 high dose, low dose and placebo, respectively. Results were 
statistically significant. 
1.3. 
Risk-Benefit Assessment 
1.3.1. Identified RZL-012 Risks 
Adverse Events 
Identified risks are local injection-site reactions including injection-site bruising, induration, 
edema, pain, and erythema which are commonly reported after injection of RZL-012. Most 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 21 of 44 
CONFIDENTIAL 
 
injection site reactions are transient and are not observed for more than 28-56 days following 
injection. None of these identified risks are serious in nature. 
Submental swelling and dysphagia have also been identified as common risks. These two are 
transient and have not been serious in nature.  
In addition, nerve damage was also reported in association with RZL-012 treatment. While these 
AEs should be carefully monitored, it is noted that there were no serious outcomes to any of these 
events and all were short-lived. 
Laboratory - D-Dimer 
Treatment with RZL-012 causes a transient increase in D-dimer without any clinically significant 
activation of the coagulation system nor any presence of Disseminated Intravascular Coagulation 
(DIC). The absence of any clinical symptoms related to elevation of D-dimer supports a direct link 
between RZL-012 induced inflammation and elevated D-dimer levels, unrelated to venous 
thromboembolic disease.  
Laboratory – ALT and AST 
RZL-012 is associated with a transient increase in AST which is seen as early as one day following 
RZL-012 treatment and has resolved by 7 days post-treatment. It is noted that the increase has not 
been associated with any increases in other liver enzymes, nor with any clinical symptoms, other 
than in one subject in study RZL-012-P0US-01.3, who received a small single dose of 20 mg of 
RZL-012. This subject demonstrated a significant transient increase in alanine aminotransferase 
(ALT) blood levels (Levels had x7-9-fold increase from the upper limit of normal (ULN) on Days 
14 and 21, respectively) and a moderate elevation of aspartate aminotransferase (AST) blood levels 
(~4 fold increase from ULN) 14 days following injection of the highest dose of active treatment 
(20 mg/subject). Resolution for AST elevated levels and reduction for ALT levels to Grade 1 
(mild), occurred 14 days following detection (i.e. 28 days after dosing). ALT levels were normal 
on the next visit on Day 56. Other liver enzymes such as GGT and alkaline phosphatase, as well 
as bilirubin levels remained within normal range. 
The relationship between RZL-012 injection and a potential increase in liver enzymes is not 
completely understood. In preclinical studies which were conducted by Raziel, a rise in AST 
enzyme levels was observed in the high doses female rat group (20 mg/rat (about 80 mg/kg), 
equivalent to a human dose >900 mg/subject), returning to normal levels within 14 days of 
recovery. Raziel Therapeutics continues to monitor closely for any changes in liver enzymes. 
1.3.2. Benefits 
The cytolytic effect of RZL-012 has been demonstrated in non-clinical in-vitro and in-vivo studies. 
When administered into subcutaneous tissue, this cytolytic effect translates into a reduction in 
subcutaneous tissue. The reduction in submental fat has been demonstrated in Phase 2a and Phase 
2b studies. Confirmatory Phase 3 studies will be conducted.  
 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 22 of 44 
CONFIDENTIAL 
 
3.0 STUDY OBJECTIVES AND ENDPOINTS 
3.1 
Study Objectives 
3.1.1 
Primary Objective 
• 
The primary objective of this study is to compare the benefits of lidocaine, methylprednisolone,  
Celecoxib + cetirizine or compression garments on RZL-012-induced adverse events. 
3.1.2 
Secondary Objectives 
• To assess the safety profile of RZL-012 of combining lidocaine, methylprednisolone ,  Celecoxib 
+ cetirizine or compression garment with RZL-012 
3.2 
Study Endpoints 
3.2.1 
Primary Endpoint 
• 
Safety profile of combining lidocaine, methylprednisolone ,  Celecoxib +cetirizine or a 
compression garment with RZL-012. 
3.2.2 
Exploratory Endpoints 
The secondary endpoints for the study are: 
• 
Proportion of subjects who have at least a 1-grade improvement in the C-CAT on Day 84 
versus baseline in subjects receiving RZL-012 alone or in combination with other 
medications.  
• 
Proportion of subjects who have at least a 1-grade improvement in the S-CAT on Day 84 
versus baseline in subjects receiving RZL-012 alone or in combination with other 
medications. 
• 
Proportion of subjects who have at least a 1-grade improvement in both C-CAT and S-CAT 
on Day 84 versus baseline in subjects receiving RZL-012 alone or in combination with other 
medications. 
• 
Proportion of subjects who have at least a 2-grade improvement in both C-CAT and S-CAT 
on Day 84 versus baseline in subjects receiving RZL-012 alone or in combination with other 
medications. 
• 
Changes in SMF volume measured by MRI scans on Day 84 versus baseline in subjects 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 23 of 44 
CONFIDENTIAL 
 
receiving RZL-012 alone or in combination with other medications. 
• 
Satisfaction in subjects receiving RZL-012 alone or in combination with other medications. 
4.0 STUDY DESIGN 
4.1 
Overall Design 
This is a Phase 2, open-label, 2-stage, adaptive-design study in which subjects will be randomized 
into one of 5 treatment groups comprised of RZL-012 with or without additional study treatments: 
1. RZL-012 alone 
2. RZL-012 and 1% lidocaine with 1:100,000 epinephrine (on Day 1) – 5ml lidocaine will be 
injected 10 minutes before RZL-012 treatment. 
3. RZL-012 and oral methylprednisolone dose pack (8 mg (2 tablets) on Day 1 before treatment 
followed by 16 mg after treatment (as per Instructions for Use)). From Day 2, a daily tapering off 
by 4 mg until Day 6 will be administered per Rx Instructions for use. 
4. RZL-012 and Celecoxib and cetirizine (200 mg Celecoxib BID and 10 mg cetirizine BID on Days 
1, 2, 3, 4, 5 and 6). 
5. RZL-012 + sling/pressure garment (until Day 6). 
In the first stage of the study, 5 subjects will be randomized into each of the treatment groups. 
Study outcomes will be assessed up to one week thereafter to determine the need to modify 
additional study treatments. Subsequently up to 10 additional subjects will be randomized into 
each of the treatment groups for the second stage of the study.   
For each subject, the study will consist of a screening period, baseline period in which subjects 
will receive a single treatment session of RZL-012 with the assigned treatment and a follow-up 
period.  RZL-012 will be administered during a single treatment session via multiple injections 
into the submental area under the chin. Subjects will thereafter be monitored for safety and efficacy 
for at least 84 days. 
Each subject will be treated with the same dose of RZL-012 : 
• RZL-012 (concentration of injected solution 50 mg/mL RZL-012) of 7.5 mg/0.15 
mL/injection point that results in a total dose/volume of 240±30mg mg/4.8±0.6 mL RZL-
012, 
Each subject will receive additional study treatments in accordance with the treatment group to 
which the subject is randomized. 
4.2 
Rationale for Study Design 
Because there are 5 different treatment arms, and subjects receive different additional study 
treatments depending on the treatment arm to which the subject is randomized, blinding of study 
treatments would be difficult. Therefore, the study will employ an open-label design. 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 24 of 44 
CONFIDENTIAL 
 
4.3 
Rationale for Study Dose 
The Phase 2b study (RZL-012-SMF-P2b-US-001) demonstrated that a single treatment session of 
RZL-012 at a maximal dose of 270 mg into the subcutaneous tissue of the submental area reduces 
fat and improves appearance of this area. Therefore, Raziel intends to proceed with this dose into 
Phase 3 clinical trials. 
5.0 STUDY POPULATION 
5.1 
Inclusion Criteria 
For a subject to be eligible for this study, he or she must meet all of the following inclusion 
criteria: 
1. Is a male or female subject between the ages of 18 and 65 years, inclusive. 
2. Has body mass index (BMI) between >22  kg/m2 and <40  kg/m2. 
3. Has SMF  bulge that is contiguous and fits to 32±4 injections sites according to a grid with 1 
centimeter (cm) distance between injection points. 
4. Has grade 3 to 4 of SMF as rated by both the C-CAT and S-CAT. 
5. Has stable weight, with no fluctuation of >5 kg in the past 12 months. 
6. If female, is not pregnant or breastfeeding based on the following: 
agree to the use of highly effective contraceptive methods for at least 2 weeks before baseline until 4 weeks after 
the last day of study drug and a negative serum pregnancy test (ß-hCG) at screening and negative urine pregnancy 
test at baseline; or  
is abstaining 
is of nonchildbearing potential defined as clinically infertile as the result of surgical sterilization (hysterectomy, 
bilateral tubal ligation, and/or bilateral oophorectomy); or  
is confirmed postmenopausal status (defined as either having amenorrhea for ≥ 12 consecutive months without 
another cause or documented serum follicle-stimulating hormone (FSH) level > 40 mIU/mL or another 
documented medical condition (e.g., was born without a uterus)) 
NOTE: The following are considered highly effective contraceptive methods: hormonal oral contraceptives, 
injectables, and patches; intrauterine devices; double-barrier methods (synthetic condom, diaphragm, or cervical 
cap used with spermicidal foam, cream, or gel); and male partner sterilization. 
7. If male (with or without vasectomy), agree to the use of highly effective contraceptive methods 
as listed above in criteria 7 as well as to use a barrier method, e.g. condom , from study check-
in until 7 days after drug injection. 
8. Is willing to avoid strenuous exercise for seven (7) days post treatment. 
9. Is able to adhere to the visit schedule and protocol requirements and be available to complete 
the study. 
10. Is willing and able to sign an Institutional Review Board (IRB) approved informed consent 
form (ICF) indicating that they are aware of the investigational nature of the study. 
 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 25 of 44 
CONFIDENTIAL 
 
5.2 
Exclusion Criteria 
Subjects must NOT meet any of the following exclusion criteria to be eligible for enrollment: 
1. Is unable to tolerate subcutaneous injections 
2. Has any systemic disease including but not limited to gastritis or ulcers, renal dysfunction, 
hypertension, liver disease, glaucoma, diabetes and/or cardiovascular disease, regardless of 
whether the condition is controlled with medication. 
3. Has any contraindications to oral corticosteroids (prednisone), NSAIDs (e.g.,  Celecoxib) or 
non-sedative antihistamines (e.g. cetirizine) 
4. Has skin laxity (i.e., elastosis, skin crepiness, skin redundancy, skin draping, vertical and/or 
horizontal skin bands and folds, blunting of cervical mental angle, loss of opposition of skin to 
underlying neck structures due to skin laxity) that could obscure the evaluation and treatment 
of SMF. 
5. Has any scars, unshaven hair, tattoos, facial hair or jewelry on or near the proposed treatment 
area. 
6. Has presence of structures or confounding factors that may interfere with assessing SMF such 
as but not limited to enlarged submandibular salivary and/or parotid glands, micrognanthia, 
chin implant, soft tissue volume augmentation of chin and/or jawline, pronounced platysmal 
bands and deep necklace lines or presence of facial jowls that could obscure the evaluation of 
SMF.  
7. Has a fat bulge under the chin that is too large to be adequately treated by 32±4 contiguous 
injections on a 1cm grid . 
8. Has a fat bulge under the chin that is of an insufficient volume to allow 32±4 injections within 
a contiguous 1 cm grid.  
9. Has significant history or current evidence of a medical, psychological or other disorder that, 
in the Investigator’s opinion, would preclude enrollment in the study. 
10. Has an active bacterial, fungal, or viral infection in the proposed treatment area. 
11. Has a pre-existing skin condition in the submental region that, at the Investigator’s discretion, 
may confound evaluation or analysis. 
12. Has previously had treatments or surgery in the submentum, such as but not limited to, focused 
ultrasound, radiofrequency, cryolipolysis, liposuction, sodium deoxycholate, or neck lift. 
13. Has pre-existing neurological or gastrointestinal condition leading to dysphagia, dysphonia, or 
facial nerve palsy. 
14. Has Dercum’s Disease. 
15. Has allergic reactions to injectables  
16. Has allergic reactions to cetirizine or Celecoxib. 
17. Has any pre-existing medical condition other than increased SMF that, at the Investigator’s 
discretion, may result in increased submental fullness, such as but not limited to, thyroid 
enlargement, goiter, cervical lymphadenopathy, etc. 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 26 of 44 
CONFIDENTIAL 
 
18. Has a planned fat reduction procedure of any variety to the submental region for the duration 
of the study. 
19. Has medication or a history of coagulopathy. 
20.  Has a history or family history of venous thrombotic disease. 
21. Has been treated chronically at least three (3) months prior to study entry with systemic steroids 
or immunosuppressive drugs. 
22. Has been treated chronically at least one (1) week prior to study entry with non-steroidal anti-
inflammatory drugs (NSAIDs)  
23. Has used anticoagulation therapies that may increase bleeding or bruising (i.e., aspirin, 
ibuprofen/Celecoxib, warfarin, vitamins, and herbal preparations) for seven (7) days prior to 
treatment. 
24. Has had treatment with botulinum toxin injections in the neck or chin area within nine (9) 
months prior to screening. 
25. Current participation or participation within three (3) months prior to the start of this study in 
a drug or other investigational research study. 
26. Claustrophobia or MRI incompatible device or implant. 
6.0 STUDY INTERVENTION 
6.1 
Study Intervention Administration 
6.1.1 
Study Intervention Description 
RZL-012 is provided as a sterile liquid solution suitable for injection. It has a concentration of 
50 mg/mL. It is packaged in glass vials and supplied in study kits. 
Subjects will be treated with additional planned treatments in accordance to their randomization 
group. In case subjects will be assigned to group 2, they will be injected with 5 mL lidocaine with 
1:100,000 epinephrine. In case subjects will be randomized to group 3 or 4 they will receive a 
prescription to buy in the pharmacy the relevant drugs, i.e. methylprednisolone dose pack (if assigned 
to group 3) and Celecoxib and cetirizine (in case assigned to group 4). This is in order to allow them 
to take the drugs at baseline visit (Day 1) prior to RZL-012 injection. Subjects will take medicines 
1-2 hours prior to RZL-012 injection and continue after RZL-012 injection per instructions for use 
for each of the medicines for a total period of 6 days. If subjects are randomized to group 5, they 
will be given with the pressure garment in the site immediately after injection and will wear the 
garment up to day 6 after injected. Description of group assignments is described in Table 2. 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 27 of 44 
CONFIDENTIAL 
 
Table 2– Study Group Treatment 
 
Group 1 
Group 2 
Group 3 
Group 4 
Group 5 
Day 1 
RZL-012 
RZL-012 + 1% 
lidocaine with 
1:100,000 
epinephrine (10  
minutes  prior to 
RZL-012) 
 
RZL-012 +  
methylprednisolone 
dose pack (the first 
dose of 2 tablets 
(8mg) is 
administered1-2 
hours prior to RZL-
012) 
 
A total of 24 mg 
(16 mg after RZL-
012, as per IFUs) 
 
RZL-012 + 
200 mg 
Celecoxib BID 
and 10 mg 
cetirizine BID 
(the 1st dose is 
administered 1-2 
hours prior to 
RZL-012). 
RZL-012 + 
pressure 
garment 
Day 2 
 
 
20 mg 
methylprednisolone 
200 mg 
Celecoxib BID 
and 10 mg  
cetirizine BID 
pressure 
garment 
Day 3 
 
 
16 mg 
methylprednisolone 
200 mg 
Celecoxib  BID 
and 10 mg 
cetirizine BID 
pressure 
garment 
Day 4 
 
 
12 mg 
methylprednisolone 
200 mg 
Celecoxib  BID 
and 10 mg 
cetirizine BID 
pressure 
garment 
Day 5 
 
 
8 mg 
methylprednisolone 
200 mg 
Celecoxib  BID 
and 10 mg 
cetirizine BID 
pressure 
garment 
Day 6 
 
 
4 mg 
methylprednisolone 
200 mg 
Celecoxib  BID 
and 10 mg 
cetirizine BID 
pressure 
garment 
BID = twice daily,  
Subjects will undergo a single treatment session with maximum 36 injections of 7.5 mg RZL-012 
each for a total RZL-012 dose of 270 mg. The total injection volume for all groups will be 4.8 
mL±0.6. 
Subjects will be injected with RZL-012 perpendicularly (90°) to the skin. An ice pack will be 
placed on the injected area for pain relief immediately after injection. Subjects will remain seated 
in the injection position for an additional 10 minutes after dosing. 
The injection pattern will be based on a submental area shaped grid in which the distance between 
rows and columns will be 1 cm, as seen in Figure 1 below. The Investigator will choose 32±4 
sequential points on the grid that will mark the injected area according to SMF fullness and 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 28 of 44 
CONFIDENTIAL 
 
convexity. The treatment area boundary: superiorly by a line 1 cm inferior to the mandibular 
margin, laterally by the sternocleidomastoid muscles, and inferiorly by the hyoid bone. 
Figure 1 
Submental Injection Pattern 
 
6.2 
Preparation/Handling/Storage/Accountability 
The RZL-012 solution is supplied ready to use. The RZL-012 kits, each comprised of 2 vials, 
should be stored in the site pharmacy or clinic at monitored room temperature conditions (22 ± 7 
°C) and protected from light. They should be kept in a secure location physically separated from 
standard clinic or office drug supplies. 
RZL-012 is administered to the subject on the study site by the study investigator. The vials should 
be manually shaken prior to injection. 
The following procedures prior to injection into the SMF will be applied: 
1. The lower face and anterior neck will be cleaned with an appropriate topical antiseptic. 
2. Ice/cold pack or topical local anesthesia (i.e., lidocaine cream) may be used prior to drug 
administration to enhance subject’s comfort. 
3. The treatment area will be bounded superiorly by a line 1 cm inferior to the mandibular 
margin, laterally by the sternocleidomastoid muscles, and inferiorly by the hyoid bone. 
4. Injection grid pattern will be applied by pressing the grid firmly onto the clean, dry skin, 
with the printed grid pattern facing the skin. The grid paper backing will be thoroughly 
wetted with a cotton pad soaked with sterile water. After 15 seconds, the grid cover will 
be peeled off. 
5. An area of 32±4 adjacent injection points will be determined following the Investigator’s 
evaluation. 
6. Syringes will be filled with 1 mL RZL-012 and the number of syringes will be compatible 
with the total volume of injection. Up to six (6) syringes for a total volume of 5.4 mL will 
be used. 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 29 of 44 
CONFIDENTIAL 
 
7. All injections will be administered perpendicularly in 90 degrees, using a 1 mL Luer-lock 
syringe and a 29G or 27G x 1/2” needle, respectively. 
8. The hole of the needle should be pointing into the middle of fat layer and the injection 
direction should be towards the earth. An attempt to pull the plunger should be made prior 
to injecting to ensure no blood is coming out. If so, the plunger should be pushed down to 
inject 0.15 ml the medicine. The formulation is viscous; therefore, resistance is expected 
during injection. 
9. Immediately following completion of the injections, an ice/cold pack will be applied for 
immediate pain relief. It will be held by the subject for at least two (2) minutes. 
10. The Investigator will record the number of injections administered for each subject. 
The injection pattern used will be based on an existing grid in the shape of the submental area, 
where distance between injection rows will be 1 cm and distance between the injection columns 
will be 1 cm.   
The number of injections for each subject will be determined by the Investigator according to 
fullness of SMF but will not be lower than 28 injections or higher than 36 injections. Total injection 
volume and number of injection per subject should be recorded on medical records. 
All study drug received by the Investigator will be inventoried and accounted for in a Dispensing 
Log. 
A maximal of 2 vials will be used for each subject. All open vials will be kept until the end of 
study when the Sponsor will determine if study drug should be returned or destroyed.  
6.3 
Study Intervention Compliance 
Study treatment consists of a single administration session administered by the study investigator.  
6.4 
Prior and Concomitant Medications 
Concomitant medications are defined as medications taken any time after the start of dosing until 
discharge assessments. All concomitant medication, including blood and blood products, dietary 
supplements, and non-prescription drugs, will be listed at screening/baseline. Each entry will 
include the treatment's start date, treatment name (generic), reason for use, dosing regimen (dose 
and frequency of use), route of administration, and stop date (if applicable). Study subjects will be 
routinely questioned for changes in the administration of concomitant medication during the trial 
and changes should be updated from medical records as well. 
7.0 STUDY INTERVENTION DISCONTINUATION 
A premature discontinuation from study will occur when a subject who signed informed consent 
ceases participation in this study, regardless of circumstances, prior to completion of the protocol. 
Subjects can be prematurely discontinued from the study for one of the following reasons:  

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 30 of 44 
CONFIDENTIAL 
 
• Failure to meet inclusion/exclusion criteria before receiving first dose of study drug has 
been administered 
• Death 
• Significant safety event that in the opinion of the Investigator warrants discontinuation. 
Raziel will attempt to follow up all subjects for safety. 
• Lost to follow-up after every attempt has been made to contact the subject, including 
sending a registered letter 
• Subject withdraws consent 
The Principal Investigator and the Institutional Review Board/Ethics Committee (IRB/EC) reserve 
the right to prematurely terminate the study in the interest of subject safety and welfare. The 
Sponsor reserves the right to prematurely terminate the study at any time for administrative 
reasons. 
8.0 STUDY ASSESSMENTS AND PROCEDURES 
8.1 
Medical History 
A medical history will be obtained at screening.  Subject’s medical history should be fully 
documented to confirm study eligibility. Medical history must include, but not limited to, past and 
present medical conditions, concomitant non-drug treatments, and hypersensitivity to drugs. 
8.2 
Height  
Height will be measured at screening.  It will be reported in centimeters. A subject’s height together 
with weight will be used to calculate a subject’s BMI. 
8.3 
Weight 
Body weight will be measured at screening, baseline (day 1) and at the study visit Day 28 and 
study visit Day 84. Weight will be reported in kilograms (kg). A subject’s weight at screening 
together with height will be used to calculate a subject’s BMI. 
8.4 
Pregnancy Tests 
A serum (ß-hCG) pregnancy test will be administered to females of childbearing potential at 
screening and a urine pregnancy test will be administered at baseline prior to dosing. Additional 
serum pregnancy tests will be done at any time during the study (up to Day 84), if pregnancy is 
suspected. Urine pregnancy test will be done to females of childbearing potential on Day 84. 
8.5 
Complete Physical Examination 
The Investigator (or medically qualified nominee) will perform a complete physical examination 
at screening and on Day 7 and  Day 84 visit.  

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 31 of 44 
CONFIDENTIAL 
 
8.6 
Clinician-Chin Assessment Tool (C-CAT) 
SMF ratings using the C-CAT will be conducted by a fixed and well-trained Investigator at 
screening and baseline (Day 1) and at study visits on Days 28, 56, and 84 to assess the change in 
SMF severity before and following treatment. 
The C-CAT score will be based on the Investigator’s clinical evaluation of the subject in the 
Frankfurt horizontal plane. Clinical evaluation will include palpation of the chin and neck area, 
anterior, oblique and profile views of the chin and neck, and observation of pronation, supination, 
and lateral movement of the head. The score will be determined using the rating scale definitions. 
The score will be recorded as a whole number. At screening, the score will be used in conjunction 
with inclusion criteria. 
The C-CAT is defined below. The scale is A 5-point scale (scored 0-4). 
The grading system categorizes 3 aspects of submental chin fat: bulge, (size of the submental fat 
bulge) neck (extension of the bulge into the neck, downward and lateral) and jawline (the 
appearance of the jawline, presence of fat and definition of the jawline). 
Each grade contains a description and a line drawing. Each grade is distinct and non-overlapping. 
A comprehensive training guide with representative photographic examples and line drawing to 
each grade will be provided to the study center sites for training and visual comparison. 
Table 3 
Clinician Chin Assessment Tool (C-CAT) 
 
8.7 
Subject – Self-Chin Assessment Tool (S-CAT) 
SMF ratings using the S-CAT will be conducted by the subject at screening and baseline (Day 1) 
and at study visits on Days 28, 56, and 84 to assess the change in SMF area following treatment. 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 32 of 44 
CONFIDENTIAL 
 
The scale has 5 grades from 0 to 4. Each grade utilizing line-drawings and descriptors to identify 
5 unique and non-overlapping grades. 
The chin fat is categorized by the following features: bulge (size of the fat bulge) neck (extension 
of the bulge downward and laterally into the neck) and jawline (presence of fat and definition of 
the jawline). 
Self evaluations should be made sitting in an upright position with the chin at a right angle (as 
illustrated in the line drawings). Mirrors will be used to see the chin, neck and jawline from both 
front and side views. 
A comprehensive training guide with representative photographic examples and line drawing to 
each grade will be provided to the subjects. 
Table 4 
Self Chin Assessment Tool (S-CAT) 
 
 
8.8 
Magnetic Resonance Imaging (MRI) 
The purpose of the MRI exam is to evaluate whether the additional treatments (i.e., lidocaine, 
Celecoxid, Zyrtic etc.) affects the fat reduction following treatment of RZL-012. MRI exams will 
be conducted in imaging centers close to selected clinical sites. 
MRI will be conducted at screening in order to establish a baseline value for assessment of 
treatment efficacy. Post-treatment period MRI will be completed within 84 days (± 14 days) after 
the treatment session. 
Quantitative measurements such as fat volume of the SMF area will be used as an objective 
parameter for measurement of SMF reduction following treatment. 
Sagittal 2D and 3D images of the head and neck (chin area) will be obtained using 1.5 Tesla 
machine (General Electric, Siemens, Phillips or other). For each MRI visit, the total imaging time 
is expected to be approximately thirty (30) minutes. 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 33 of 44 
CONFIDENTIAL 
 
During the imaging, subjects will be positioned in Head first Supine recumbent. Images in the 
sagittal plane across the entire submental region will be collected using an appropriate MR 
sequence to minimize the effects of air cavities, dental implants, and amalgam on the resultant MR 
image. This imaging approach will generate a 2D and 3D image data set that allows for the 
quantification of the SMF volume in several slices covering the treatment area. In the follow up 
MRI exam, slices will be positioned as similar as possible to the first MRI exam. 
Images should be saved in a DICOM format and include the date completed and subject’s 
screening number to be transferred home the Sponsor’s request for central analysis. 
Submental volume analysis will be performed by computer-assisted tools and calculation of 
submental volume will be completed prior to dosing and after treatment. 
8.9 
2-D Standardized Photography  
Standardized photography (2-dimensional) of the face (SMF area) will be conducted at screening 
and on study visits Day 2, Day 4, Day 7, Day 14, Day 21, Day 28, Day 56, and Day 84.  
Photographs will be taken with a digital camera according to photography standards in 
dermatology surgeries for the face/neck area (see Appendix A). 
8.10 
Subject’s Satisfaction Questionnaire  
Subject’s satisfaction questionnaire (yes/no questions) will be conducted by the subjects at 
screening and on study visits Day 28, Day 56 and Day 84.  
Subjects will be asked the following questions and will score their satisfaction based on the grades 
below: 
How satisfied are you currently with the appearance of your chin, neck and jawline area? 
Score 
Grade 
0 
Extremely Satisfied 
1 
Satisfied 
2 
Somewhat satisfied 
3 
Neither Satisfied nor Dissatisfied 
4 
Somewhat Dissatisfied 
5 
Dissatisfied 
6 
Extremely Dissatisfied 
How happy are you with the appearance of your neck as it relates to your chin fat? 
Score 
Grade 
0 
Extremely Satisfied 
1 
Satisfied 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 34 of 44 
CONFIDENTIAL 
 
2 
Somewhat satisfied 
3 
Neither Satisfied nor Dissatisfied 
4 
Somewhat Dissatisfied 
5 
Dissatisfied 
6 
Extremely Dissatisfied 
 
How satisfied are you with the result of your treatment*? 
Score 
Grade 
0 
Very satisfied 
1 
Satisfied 
2 
Somewhat satisfied 
3 
Somewhat dissatisfied 
4 
Dissatisfied 
5 
Very dissatisfied 
How likely would you be to recommend this procedure to friends and family*? 
Score 
Grade 
0 
Extremely likely 
1 
Very likely 
2 
Somewhat likely 
3 
A little likely 
4 
Not at all likely 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 35 of 44 
CONFIDENTIAL 
 
8.11 
Biochemistry 
Blood samples for the laboratory evaluation of biochemistry parameters will be collected at 
screening and at study visits Day 2, Day 7, 28 and Day 84. 
If there are clinically significant alerts obtained on Day 7, an unscheduled visit will be added for 
additional blood sampling. 
Complete blood cell count (CBC) will include a standard red blood cell (RBC), white blood cell 
(WBC) with differential, hemoglobin, hematocrit, platelets. A comprehensive metabolic panel will 
include serum alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), glucose, calcium, globulin (calculated), phosphorus, chloride, sodium, 
potassium, blood urea nitrogen (BUN)/creatinine ratio (calculated), creatinine with GFR 
estimated,  total bilirubin, albumin, albumin/globulin ratio (calculated), total protein, amylase, 
bicarbonate/carbon dioxide (CO2), uric acid, gamma-glutamyl transferase (GGT), and lactate 
dehydrogenase (LDH).  
Biochemistry parameters will be collected for safety assessments. 
8.12 
Vital Signs 
Vital signs (systolic and diastolic sitting position blood pressure, pulse rate, respiratory rate, and 
body oral temperature) will be obtained at screening, baseline (pre and post dose) and at study 
visits Day 2, Day 4, Day 7, Day 14, Day 21,  Day 28, Day 56 and Day 84. 
Vital signs will be collected for safety assessments. 
8.13 
ECG 
ECG tests will be performed at screening and at study visits Day 7 and Day 84. ECG will be 
performed in triplicates. 
ECGs will be collected for safety assessments. 
8.14 
Visual Analog Scale (VAS) 
Pain will be assessed as part of the AEs using Visual Analog Scale (VAS). A scale between 0 to 
10 will describe the pain level, where 0 represents no pain and 10 score is intolerable pain. A score 
of 1-3 is categorized as mild, 4-6 is moderate and 7-10 is severe. VAS will be assessed on Day 1 
(after injection), Day 2, Day 4, Day 7, Day 14, Day 21, Day 28, Day 56 and Day 84. 
8.15 
Adverse Events and Serious Adverse Events 
8.15.1 
Collection of Adverse Events Data 
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with 
the use of an investigational (medicinal) product (IP) or other protocol-imposed intervention, 
regardless of attribution.  An AE may include intercurrent illnesses or injuries that represent an 
exacerbation (increase in frequency, severity, or specificity) of pre-existing conditions (e.g., 
worsening of asthma).  A laboratory abnormality will be reported on the “Adverse Event” case 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 36 of 44 
CONFIDENTIAL 
 
report forms only if it is associated with clinical sequelae or requires therapeutic intervention.  
Whenever possible, it is preferable to record a diagnosis as the AE term rather than a series of 
symptoms relating to a diagnosis.  AEs will be coded according to the Medical Dictionary for 
Regulatory Activities (MedDRA) and graded for severity. In case the AE severity is changed from 
one severity grade to the another the date of AE start and AE end of the specific AE severity should 
be recorded.  
The reporting period for AEs starts after dosing of study drug and will end at final study visit. If 
an AE remains unresolved at discharge, the subject will be followed, at the Investigator’s 
discretion, until resolution of the event or until the subject is deemed “lost to follow-up”.    SAEs 
must be followed until resolution by the PI, even if this extends beyond the study-reporting period.  
Resolution is defined as the return to baseline status or stabilization of the condition with the 
expectation that it will remain chronic. 
The Investigator will assess AEs for severity, relationship to IP, and as to whether the event meets 
one or more of the definitions of an SAE.  The assessments will be recorded on the source 
documents and AE CRF, using the categories defined below.  
Causality 
Category 
Description 
Unrelated 
A clinical event, including laboratory test abnormality, with a 
temporal relationship to drug administration which makes a causal 
relationship improbable, and in which other drugs, chemicals or 
underlying disease provide plausible explanations. For the purpose of 
this protocol, the term unlikely will be considered not related to study 
medication and an “Adverse Event”. 
Related 
A clinical event, including laboratory test abnormality, with a 
reasonable time sequence to administration of the drug, but which 
could also be explained by concurrent disease or other drugs or 
chemicals. Information on drug withdrawal may be lacking or unclear. 
For the purpose of this protocol, an event that has possible or probable 
relationship to study medication will be defined as a “Suspected 
Adverse Drug Reaction”.   
In order to classify AEs and diseases, preferred terms will be assigned by the sponsor or its 
designee to the original terms entered on the CRF, using MedDRA. 
AEs will be graded for severity according to the following definitions: 
Table 5 
Severity Assessment of Adverse Events  
Common Term 
Description 
Mild 
Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated. 
Moderate 
Moderate; minimal, local or noninvasive intervention indicated; 
limiting age-appropriate instrumental Assisted Daily Living 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 37 of 44 
CONFIDENTIAL 
 
Common Term 
Description 
(ADL). 
Severe 
Severe or medically significant but not immediately life-
threatening; hospitalization or prolongation of hospitalization 
indicated; disabling; limiting self-care ADL. 
Life-Threatening 
Life-threatening consequences; urgent intervention indicated. 
Death 
Death related to AE  
8.15.2 
Serious Adverse Events 
According to the ICH Guidelines for Good Clinical Practice (E6), an SAE is any untoward 
medical occurrence during the course of a clinical investigation that is characterized by one or 
more of the following: 
• Results in death 
• Is life-threatening 
• Requires in-subject hospitalization or prolongation of existing hospitalization 
• Results in persistent or significant disability/incapacity 
• Is a congenital anomaly/birth defect 
• Important medical events 
Although not an SAE, exposure to study drug during pregnancy, even if no AE is reported in the 
mother, should be reported within 24 hours. 
8.15.3 
Reporting Requirements for Serious Adverse Events 
All SAEs must be reported to the Sponsor by the Investigator, study coordinator, other designated 
study personnel, or clinical research associate within 24 hours of notification of the SAE. To report 
such events, an SAE form must be completed by the Investigator and sent within 24 hours by email 
or fax with relevant information. 
Within the 48 hours following the initial report, the Investigator must provide further information 
on the SAE if available. This should include a copy of the completed SAE form, and any other 
information that will assist the understanding of the event. Significant new information on ongoing 
SAEs should be provided promptly as a follow-up. 
The Investigator also must report all SAEs promptly to the appropriate IRB/EC as required by 
the institution within 24 hours or 48 hours if on weekend/holiday. 
Report SAEs by: 
 
 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 38 of 44 
CONFIDENTIAL 
 
Report SAEs by  
SAE Hotline: 888-746-7231 
SAE Fax Line: 888-746-3293 
SAE Email: rho_productsafety@rhoworld.com 
 
Table 6 
Contact Information for SAE Reporting 
Primary Contact 
Sponsor Contact 
Lead Product Safety Specialist 
Medical Monitor: 
Bonnie Graham, RN, BSN 
Patricia Walker, MD 
Mobile: 
Mobile: 
Mobile: 
1-805-705-5853 
Email: 
Email: 
Email: 
dr.patricia.walker@gmail.com 
8.15.4 
Reporting pregnancy 
Pregnancy testing must be performed on all women of childbearing potential prior to dosing, and 
all the results of all pregnancy tests are to be recorded in the eCRF’s. All women must have a 
negative pregnancy test to be enrolled into the study. If a pregnancy test turns positive after study 
drug treatment, the patient will be discontinued and protocol-required procedures for study 
discontinuation and follow-up must be performed. The subject will be followed to determine the 
outcome of the pregnancy.  All women of childbearing potential should be instructed to contact 
the investigator if they suspect they might be pregnant (e.g. missed or late menstrual period) at any 
time during the study.  
The investigator must notify the sponsor of any pregnancies in accordance with the SAE reporting 
procedures described in section 8.14.3.  Note, while the pregnancy is not considered an AE or an 
SAE, any pregnancy complication or newborn complication will be reported as an AE or SAE if 
it meets the criteria.  Follow-up information regarding the course of pregnancy, including perinatal 
and neonatal outcomes and, where applicable, offspring information must be reported on the 
Pregnancy Outcome eCRF.   
8.15.5 
Recording of Serious Adverse Events 
All SAE information must be recorded on the SAE form provided by the Sponsor. Additional 
follow-up information (e.g., test results, autopsy, and discharge summary) must be obtained to 
supplement the SAE report form. A copy of all initial and follow-up reports must be filed with the 
subject’s eCRF. 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 39 of 44 
CONFIDENTIAL 
 
9.0 STATISTICAL CONSIDERATIONS 
9.1 
Sample Size Determination 
A total of 75 subjects will be included in the study. All subjects will be treated with RZL-012. 
Each 15 subjects will be randomized into each of the treatment groups. 
9.2 
Analysis Data Sets 
Subjects who receive study treatment will be included in the safety analyses.  
9.3 
Endpoints Analyses 
All measured variables and derived parameters will be listed individually and, if appropriate, 
tabulated by descriptive statistics. 
For categorical variables, summary tables will be provided giving sample size, absolute and 
relative frequency, and 95% confidence interval (CI) for proportions by study arm. 
For continuous variables, summary tables will be provided giving sample size, arithmetic mean, 
standard deviation, coefficient of variations (CV%), median, minimum and maximum, and 95% 
CI for means of variables by study arm. 
Primary endpoint and exploratory endpoints  will be analyzed in descriptive manner. 
The data will be analyzed using the SAS version 9.4 (SAS Institute, Cary North Carolina). 
9.4 
Safety 
Safety data will be summarized by dose group and based on their initial dose level or treatment 
group (i.e., if a dose reduction occurs, they will be considered in their initial group). Descriptive 
statistics will be provided for actual values and change from baseline values for vital signs, blood 
parameters, ECG. 
AE assessment and treatment area evaluation including, but not limited to evaluation of edema, 
pain, bruising, erythema, induration, numbness, paresthesia, tenderness, and pruritus. Pain in the 
injection site will be assessed by Visual Analog Scale (VAS) in each of the visits. Injection site 
pain will not be recorded as an AE. 
The incidence and severity of AEs reported during the study and their relationship to study drug 
will be tabulated. AEs will be coded using MedDRA™ and will be presented by body system.  
AEs related to nerve damage such as: paralysis, mandibular neuropathy, facial palsy will be AEs 
with special interest, i.e., the PI will write a detailed narrative on these specific AEs. 
AE data will be listed individually and summarized by SOC and by PT within a system organ 
class. 
Skin irritancy AEs related to the injection procedure will be evaluated for frequency, severity and 
duration by treatment group.  
Laboratory tests and ECG results will be summarized in appropriate table. 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 40 of 44 
CONFIDENTIAL 
 
10.0 
DATA COLLECTION, STUDY MONITORING, AND DATA DISCLOSURE 
10.1 
Data Collection and Reporting 
An eCRF will be completed for each subject who receives at least one dose of study drug. All 
entries on the eCRF must be supported by original source documentation (e.g., laboratory reports, 
medical records) maintained at the investigational site. 
The Investigator will make all safety assessments (AEs and vital signs) on an ongoing basis. The 
Investigator is required to review all entries on the eCRF and sign at appropriate time intervals. 
10.2 
Study Monitoring 
All aspects of the study will be monitored carefully by the Sponsor’s designees with respect to 
current Good Clinical Practice (GCP) and Standard Operating Procedures (SOP) for compliance 
with applicable government regulations. It is the responsibility of the Investigator to provide all 
study records, including eCRFs, source documents, etc., for review and source document 
verification by the clinical monitor. 
All eCRFs will be 100% source verified against corresponding source documentation (e.g., office 
and clinical laboratory records) for each subject. Clinical monitors will evaluate periodically the 
progress of the study, including the verification of appropriate consent form procedures, review of 
drug accountability and preparation procedures, adherence to dosing procedures, and the 
verification of the accuracy and completeness of eCRFs. Clinical monitors will also ensure that all 
protocol requirements, applicable FDA regulations, other requirements, and Investigator’s 
obligations are being fulfilled. 
10.3 
Audit and Inspection 
The sponsor or representative may conduct audits at the trial site(s). Audits will include, but are 
not limited to protocol compliance, drug supply, presence of required documents, the informed 
consent process, and comparison of eCRFs with source documents. The investigator agrees to 
participate with audits conducted at a reasonable time in a reasonable manner. 
Regulatory authorities worldwide may inspect the trial site during or after the trial. The investigator 
should contact the sponsor immediately if this occurs and must fully cooperate with the inspections 
conducted at a reasonable time in a reasonable manner.  
10.4 
Deviation from Clinical Trial Protocol 
Deviations from the protocol are to be avoided. If a deviation occurs, the Investigator must 
promptly report the deviation to the study monitor. 
The Investigator (or designee) will record any failure to follow the protocol because of any other 
medical unavoidable reason to avoid the subject's urgent risk and record a document as soon as 
possible stating this and the reason. It must be submitted to the sponsor and the director of the 
study site. 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 41 of 44 
CONFIDENTIAL 
 
10.5 
Retention of Records 
The Investigator must retain all study records required by Raziel and by the applicable regulations 
in a secure and safe facility. The Investigator must notify Raziel of any change in the location, 
disposition or custody of the study files. The Investigator /institution must take measures to prevent 
accidental or premature destruction of essential documents, that is, documents that permit 
evaluation of the conduct of a study and the quality of the data produced, including paper copies 
of study records (e.g., subject charts) as well as any original source documents that are electronic 
as required by applicable regulatory requirements. 
All study records must be retained until whichever is the later day in the following: (1) At least the 
date of approval for the drug or (2) the date when 3 years have passed since the discontinuation or 
completion of the study. No records relating to this study should be disposed of without the written 
approval of Raziel. It is the responsibility of Raziel to inform the Investigator/institution as to when 
these documents no longer need to be retained. 
10.6 
Data Disclosure and Subject Confidentiality 
Subject medical information and video recordings obtained as a result of this study is considered 
confidential and used only for study evaluation purposes. Disclosure to third parties other than 
those noted below is prohibited. All reports and communications relating to subjects in this study 
will identify each subject only by number. Medical information resulting from a subject’s 
participation in this study may be given to the subject’s personal physician or to the appropriate 
medical personnel responsible for the subject’s welfare. Data generated as a result of this study are 
to be available for inspection on request by FDA or other government regulatory agency auditors, 
the Sponsor clinical monitor (or designee), and the IRB/EC. 
All laboratory specimens, evaluation forms, reports, and other records that leave the site will be 
identified by a coded number to maintain subject confidentiality. All records will be kept in a 
locked and secured area. All computer entry and networking programs will be identifiable only by 
coded numbers. Clinical information will not be released without written permission from the 
subject, except as necessary for monitoring by the IRB, the FDA, or other government authorities 
where the clinical data will be used for new drug registration, or the study Sponsor. 
Any information, inventions, or discoveries (whether patentable or not), innovations, suggestions, 
ideas, and reports, made or developed by the Investigator(s) as a result of conducting this study 
shall be promptly disclosed to the Sponsor and shall be the sole property of the Sponsor. The 
Investigator agrees, upon the Sponsor’s request and at the Sponsor's expense, to execute such 
documents and to take such other actions, as the Sponsor deems necessary or appropriate, to obtain 
patents in the Sponsor’s name covering any of the foregoing. 
The results of this study will be published under the direction of the Sponsor. Results will not be 
published without prior review and approval by the Sponsor and Study Investigator. 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 42 of 44 
CONFIDENTIAL 
 
11.0 
PROTECTION OF HUMAN SUBJECTS 
11.1 
Basic Principles 
The study will be conducted in accordance with the relevant regulatory requirements, this protocol, 
and ethical principles that are consisted with the GCP guideline developed by the International 
Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for 
Human Use (ICH). This clinical trial will also be conducted in compliance with Declaration of 
Helsinki, protocol, Standard specified in the relevant local regulations. Prior to initiation of the 
study, the investigator and the sponsor should obtain approval from the IRB/IEC on this protocol 
and any further amendments, and the subject information and informed consent form. 
Any suspected serious breaches must be immediately reported to the sponsor. A serious breach is 
a breach of the conditions and principles of GCP in connection with the study or the protocol, 
which is likely to affect, to a significant degree, the safety of the subjects or the scientific value of 
the study. 
Personnel involved in the study will be qualified by education, training, and experience to 
perform their respective tasks. 
11.2 
Institutional Review Board/Ethics Committee 
The Investigator or designee agrees to provide the IRB/EC with all appropriate material, including 
a copy of the ICF. The study will not be initiated until the Investigator obtains written approval of 
the research plan and the ICF from the appropriate IRB/EC and copies of these documents are 
received by the Sponsor. Appropriate reports on the progress of this study will be made by the 
Investigator to the IRB/EC and Sponsor in accordance with applicable government regulations and 
in agreement with the policies established by the Sponsor. The Sponsor ensures that the IRB/EC 
complies with the requirements set forth in 21 CFR Part 56 (Code of Federal Regulations). 
11.3 
Informed Consent 
Prior to initiation of any study procedures, each subject will undergo an Informed Consent process 
in which the subject voluntarily confirms their willingness to participate in the trial. The 
Investigator or his/her approved designee must explain the nature of the study protocol and 
associated risks to the potential study participant. The potential participant must be allowed to 
review the study information and to ask questions before being asked to sign the Informed Consent 
Form (ICF). Written informed consent must be provided by the potential study participant prior to 
initiation of any screening evaluations or other study-related procedures. The signature date and 
the name of the individual at the site who obtained the informed consent will be recorded in the 
subject’s medical record. 
The ICF approved by the IRB/EC will contain a description of the study’s purpose, purpose, 
procedures, inconveniences and potential risks, and anticipated benefits. Prior to participation in 
the trial, the subject will receive a copy of the signed and dated written ICF. During participation 
in the trial, the subject will receive a copy of the signed and dated consent form updates and a copy 
of any amendments to the ICF provided to the subjects. 

Raziel Therapeutics, Ltd. 
Protocol RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
15 November  2022 
Page 43 of 44 
CONFIDENTIAL 
 
After written informed consent is obtained, the subject will be assigned a screening number and 
will undergo the designated screening procedures listed in Section 1.2. The Investigator, sub-
investigator or delegate will assess the results of these screening evaluations to determine 
eligibility for entry into the study according to the inclusion/exclusion criteria listed in Section 5.0. 
11.4 
Subject Health Injury and Insurance 
In general, if a subject is health-injured as a direct result of the investigational products, the sponsor 
or its contracted insurance company will pay for reasonable and necessary medical treatment for 
the health-injury. If laws or regulations of the locality in which the study is taking place require 
additional payment of expenses, the sponsor should comply with such laws or regulations. Where 
applicable, the sponsor will arrange for specific insurance coverage. If health damage occurred in 
subject participating the clinical trial due to the willful or gross negligence of investigator’s site, 
indemnification will be discussed based on the contract with the site. The indemnification for the 
health damage and the payment to subjects will be described in the ICF. 
11.5 
Completion of the Study 
If the clinical trial is completed at the study site, the investigator will notify the director of the 
study site that the trial has been completed and provide an approximate summary in writing.  The 
director of the study site will promptly notify the IRB/EC and the Sponsor in writing about the 
completion. 
 

Raziel Therapeutics, Ltd. 
Protocol RZL-012- RZL-012-SMF-SWMTG-P2US-001 
RZL-012 
Version: 1.2 
 
15 November 2022                                              44 of 44                                                CONFIDENTIAL 
                                   
 
Appendix A:  Photographic Standards of the Face Area